Imaging and biomarker-based risk stratification in TAVI: the role of epicardial fat, visceral fat, and adiponectin
European Heart Journal Open · 18.05.2026 · 6 (3)
DOI: 10.1093/ehjopen/oeag085 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Heart Journal Open, online erschienen am 29.05.2026. Verfasst von Tatyana Storozhenko und 11 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Center Aalst, Moorselbaan 164, Aalst 9300, Belgium. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Aims
Transcatheter aortic valve implantation (TAVI) has become a standard treatment for severe aortic stenosis, yet clinical outcomes vary significantly. Epicardial adipose tissue (EAT), visceral adipose tissue (VAT), and circulating adiponectin may contribute to this heterogeneity. This study aimed to determine how adipose tissue characteristics, in combination with adiponectin levels, affect clinical outcomes following TAVI. Methods and results This single-centre retrospective study included 243 patients with severe aortic stenosis who underwent TAVI. Pre-procedural computed tomography scans were processed using artificial intelligence to quantify EAT density (EATHU) and VAT area at the level of the L3 vertebra (VATL3A). Patients were stratified into groups based on median adiponectin (6.54 µg/mL), VATL3A (135 mm), EATHU (−82.0 HU), and EATVOL (31 mL). The primary endpoint was 1-year major adverse cardiac and cerebrovascular events (MACCE), defined as all-cause mortality, heart failure hospitalization, or stroke. Over a mean follow-up of 344 ± 77 days, there were 25 deaths (10%), 12 heart failure hospitalizations (5%), and 7 strokes (3%). Circulating adiponectin (adjusted HR 1.34 per 5 μg/mL, 95% CI 1.05–1.70; P = 0.017) and VATL3A (adjusted HR 0.63 per 100 mm2, 95% CI 0.44–0.91; P = 0.014) independently associated with MACCE, EATHU, and EATVOL did not. All three combined adipose–adiponectin phenotypes demonstrated significant graded risk (P-for-trend 0.003–0.048), with the high EATVOL/high adiponectin phenotype showing the strongest association (adjusted HR 4.25, 95% CI 1.80–10.07).
Conclusion
Circulating adiponectin and VATL3A independently predict 1-year MACCE after TAVI. EAT parameters become prognostically informative only when combined with adiponectin.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cardiovascular Center Aalst, Moorselbaan 164, Aalst 9300, Belgium.
- Department of Prevention and Treatment of Emergency Conditions, L.T. Malaya Therapy National Institute NAMSU, 2a Lyubovi Maloy Avenue, Kharkiv 61039, Ukraine.
- Department of Clinical and Molecular Medicine, Sapienza University, Via Giorgio Nicola Papanicolau, Rome 00189, Italy.
- Department of Advanced Biomedical Sciences, University Federico II, Via Sergio Pansini 5, Naples 80131, Italy.
ORCID-Profile: Tatyana Storozhenko, Raffaella Mistrulli, Sara Corradetti, Liesbeth Rosseel, Marc Vanderheyden
Zitieren
APA
Storozhenko, T., Buytaert, D., Mistrulli, R., Viscusi, M. M., Corradetti, S., Fiori, E., Delrue, L., Beles, M., Bartunek, J., Rosseel, L., Wyffels, E., & Vanderheyden, M. (2026). Imaging and biomarker-based risk stratification in TAVI: the role of epicardial fat, visceral fat, and adiponectin. European Heart Journal Open, 6(3). https://doi.org/10.1093/ehjopen/oeag085
Vancouver
Storozhenko T, Buytaert D, Mistrulli R, Viscusi MM, Corradetti S, Fiori E, et al. Imaging and biomarker-based risk stratification in TAVI: the role of epicardial fat, visceral fat, and adiponectin. European Heart Journal Open. 2026;6(3). doi:10.1093/ehjopen/oeag085
BibTeX
@article{Storozhenko2026,
author = {Storozhenko, Tatyana and Buytaert, Dimitri and Mistrulli, Raffaella and Viscusi, Michele Mattia and Corradetti, Sara and Fiori, Emiliano and Delrue, Leen and Beles, Monika and Bartunek, Jozef and Rosseel, Liesbeth and Wyffels, Eric and Vanderheyden, Marc},
title = {Imaging and biomarker-based risk stratification in TAVI: the role of epicardial fat, visceral fat, and adiponectin},
journal = {European Heart Journal Open},
year = {2026},
volume = {6},
number = {3},
doi = {10.1093/ehjopen/oeag085}
}
EUVIMED